Physician profile
Avery Bancroft Arons
NPI 1114762309
$540.87
in general payments reported to CMS, 2019-2025
12 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $184 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $110.67 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $98.90 | 2025 | Jynarque |
| Abbvie INC. | $82.84 | 2025 | |
| Glaxosmithkline, LLC. | $38.96 | 2025 | Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $38.21 | 2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $37.43 | 2025 | Ozempic |
| Dexcom, INC. | $36.77 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $25.58 | 2025 | Qutenza |
| Janssen Biotech, INC. | $20.83 | 2025 | Tremfya |
| Abiomed | $20.11 | 2024 | Impella |
| Travere Therapeutics, INC. | $15.95 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.62 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Arons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.